Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.53 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | TP53 | P04637 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2412341 | 0.77 | RAB9A (0.46) | ALDH1A1HSD17B10NPC1RAB9ATP53 | |
| SCHEMBL2670835 | 0.75 | TP53 (0.48) | ALDH1A1CYP1A2CYP3A4HSD17B10NPC1 | |
| SCHEMBL21408767 | 0.74 | S1PR1 (0.41) | — | |
| SCHEMBL12489671 | 0.73 | HPGDS (0.41) | CHRNB2CHRNA4CYP2A6CYP1A2NPC1 | |
| SCHEMBL31433160 | 0.73 | HPGDS (0.41) | CHRNB2CHRNA4CYP2A6CYP1A2NPC1 | |
| SCHEMBL2274986 | 0.71 | NPC1 (0.76) | ALDH1A1CYP2A6CYP1A2CYP3A4HSD17B10 | |
| SCHEMBL29419014 | 0.71 | CYP2A6 (1.00) | ALDH1A1CYP2A6CYP1A2CYP3A4HSD17B10 | |
| SCHEMBL120088 | 0.71 | CYP2A6 (1.00) | ALDH1A1CYP2A6CYP1A2CYP3A4HSD17B10 | |
| SCHEMBL30473120 | 0.71 | CYP2A6 (1.00) | ALDH1A1CYP2A6CYP1A2CYP3A4HSD17B10 | |
| SCHEMBL31417868 | 0.71 | HSD17B1 (0.44) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018123-A1 | Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation | SINDKHEDKAR MILIND D | 2009-01-15 | — | — | US | claimed |
| EP-1912980-A2 | OXAZOLIDINONES BEARING ANTIMICROBIAL ACTIVITY COMPOSITION AND METHODS OF PREPARATION | Wockhardt Limited (IN) | 2008-04-23 | — | — | EP | claimed |
| WO-2007023507-A2 | OXAZOLIDINONES BEARING ANTIMICROBIAL ACTIVITY COMPOSITION AND METHODS OF PREPARATION | WOCKHARDT LIMITED (IN) | 2007-03-01 | — | — | WO | claimed |
| EP-1503997-A1 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2005-02-09 | — | — | EP | claimed |
| WO-2003097617-A1 | CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2003-11-27 | — | — | WO | claimed |
| US-20250002487-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | VENTUS THERAPEUTICS U.S., INC. (US) | 2025-01-02 | — | — | US | disclosed |
| US-20210246147-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2021-08-12 | — | — | US | disclosed |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| EP-3587406-B1 | 2-HYDROXY-1-{4-[(4-PHENYLPHENYL)CARBONYL]PIPERAZIN-1-YL}ETHAN-1-ONE DERIVATIVES AND RELATED COMPOUNDS AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER | FORMA THERAPEUTICS INC (US) | 2021-01-27 | — | — | EP | disclosed |
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2020-11-05 | — | — | US | disclosed |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20110028448-A1 | PYRIDINE COMPOUNDS | ACTELON PHARMACEUTICALS LTD. (CH) | 2011-02-03 | — | — | US | disclosed |
| EP-2262799-A1 | PYRIDINE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2010-12-22 | — | — | EP | disclosed |
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-01 | — | — | US | disclosed |
| WO-2009109906-A1 | PYRIDINE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-11 | — | — | WO | disclosed |
| CN-101522670-A | Pyridin-3-yl derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | disclosed |
| EP-2069335-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008029370-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
| EP-0641797-A1 | Cephem derivatives and antimicrobial agents containing the same | KATAYAMA SEIYAKUSYO CO. Ltd. (JP) | 1995-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200347025-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | CHRNB2 2811/4885CHRNA5 2197/4885CHRNA4 2769/4885 |
| US-20250002487-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CGAS, TDP1, CYP11B2 | CHRNB2 2274/4885CHRNA5 2983/4885CHRNA4 3362/4885 |
| US-20090018123-A1 | Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation | POLL, POLM, POLRMT | CHRNB2 4395/4885CHRNA5 4333/4885CHRNA4 3718/4885 |
| US-20210246147-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | CHRNB2 2395/4885CHRNA5 1070/4885CHRNA4 1706/4885 |
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | CD4, FCGRT, CD47 | CHRNB2 2853/4885CHRNA5 2532/4885CHRNA4 2482/4885 |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | CHRNB2 3004/4885CHRNA5 2694/4885CHRNA4 3264/4885 |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | CHRNB2 2811/4885CHRNA5 2197/4885CHRNA4 2769/4885 |
| US-20110028448-A1 | PYRIDINE COMPOUNDS | CD47, ICOS, NFATC1 | CHRNB2 3946/4885CHRNA5 2302/4885CHRNA4 2022/4885 |
| US-10800750-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | CHRNB2 2811/4885CHRNA5 2197/4885CHRNA4 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.